依达拉奉联合七叶皂苷钠治疗脑出血的临床观察  

Clinical observation of edaravone combined with sodium aeseinate in treatment of patients with intra- cerebral hemorrhage

作　　者：高传生[1] 陈信东[1] 王萍萍[1] 祝炳军[1] 张承平[1] 

机构地区：[1]绍兴文理学院附属医院神经内科,浙江绍兴312000

出　　处：《中国中西医结合急救杂志》2012年第1期36-38,共3页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

摘　　要：目的探讨依达拉奉联合七叶皂苷钠治疗脑出血的临床疗效。方法64例脑出血患者随机分为两组。观察组（32例）采用依达拉奉30mg静脉滴注，每日2次；七叶皂苷钠20mg静脉滴注，每日1次；以及常规内科保守治疗；对照组（32例）采用常规内科保守治疗，于治疗前及治疗后14d、28d进行疗效评定。结果观察组治疗后14d、28d神经功能缺损程度评分（NDS，分）较治疗前明显改善（18．91±6．85、11．20±8．46比25．60±6．32，均P〈0．01），总有效率较对照组明显提高（75．0％比53．1％，P〈0．01），病死率较对照组明显降低（12．5％比21．9％，P〈0．01）。结论依达拉奉联合七叶皂苷钠治疗脑出血安全、可靠、疗效好。Objective To investigate the clinical effects of edaravone combined with sodium aeseinate and conservative medical treatment in treating patients with intra-cerebral hemorrhage. Methods Sixty-four cases with intra-cerebral hemorrhage were divided into the trial （ 32 cases ） and control groups （ 32 cases ）. The patients in the trial group were treated by edaravone 30 mg intravenous （ IV ） drip twice a day combined with sodium aeseinate 20 mg IV drip once a day and conservative medical treatment, while those of the control group were treated by conservative treatment alone. The clinical neurologic function deficit score （ NDS ） were compared before treatment, and the rates of effects and mortality were compared in 14 days and 28 days after treatment between the two groups. Results After treatment, the NDS was significantly improved in the trial group compared with that before the treatment （ 18.91±6.85, 11.20±8.46 vs. 25.60±6.32, both P〈 0.05） , the total effective rate was 75.0% and mortality rate was 12.5%; in the control group, the effective rate was 53.1% and mortality rate was 21.9 %, there were significant differences compared with two groups （ both P〈0.01 ）. Conclusion Edaravone combined with sodium aeseinate is a safe and effective method in treating patients with intra-cerebral hemorrhage.

关 键 词：脑出血 依达拉奉 七叶皂苷钠 临床疗效 

分 类 号：R285.6[医药卫生—中药学] R743.34[医药卫生—中医学]